Arecor Therapeutics plc (AIM:AREC)
London flag London · Delayed Price · Currency is GBP · Price in GBX
57.00
+0.50 (0.88%)
Aug 1, 2025, 4:35 PM GMT+1

Arecor Therapeutics Company Description

Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom.

The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products.

It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products.

In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection.

It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery.

Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Arecor Therapeutics plc
CountryUnited Kingdom
Founded2007
IndustryBiotechnology
SectorHealthcare
Employees44
CEOSarah Howell

Contact Details

Address:
Chesterford Research Park
Little Chesterford, CB10 1XL
United Kingdom
Phone44 1223 426 060
Websitearecor.com

Stock Details

Ticker SymbolAREC
ExchangeLondon Stock Exchange AIM
Fiscal YearJanuary - December
Reporting CurrencyGBP
ISIN NumberGB00BMWLM973
SIC Code2836

Key Executives

NamePosition
Sarah HowellChief Executive Officer
David EllamChief Financial Officer